Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHA:600671)
21.79
+0.17 (0.79%)
Sep 30, 2026, 3:00 PM CST
SHA:600671 Revenue
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd had revenue of 54.97M CNY in the quarter ending June 30, 2026, with 7.14% growth. This brings the company's revenue in the last twelve months to 207.51M, down -20.60% year-over-year. In the year 2025, Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd had annual revenue of 211.75M, down -2.55%.
Revenue (ttm)
207.51M
Revenue Growth
-20.60%
P/S Ratio
12.79
Revenue / Employee
529.37K
Employees
392
Market Cap
2.65B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 211.75M | -5.54M | -2.55% |
| Dec 31, 2024 | 217.30M | 95.52M | 78.44% |
| Dec 31, 2023 | 121.78M | 12.87M | 11.82% |
| Dec 31, 2022 | 108.91M | -38.16M | -25.95% |
| Dec 31, 2021 | 147.07M | -59.56M | -28.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Pharmaceutical Group Company | 54.82B |
| Zhejiang Int'l Group | 34.20B |
| Zhejiang Zhenyuan Share | 1.86B |
| Shanghai Shenqi Pharmaceutical Investment Management | 1.84B |
| Hangzhou Minsheng Healthcare | 854.51M |
| Chongqing Lummy Pharmaceutical | 748.94M |
| Hubei Guangji Pharmaceutical | 651.57M |
| Hangzhou Bio-Sincerity Pharma-Tech | 650.08M |